{"id":70664,"date":"2026-05-12T08:56:17","date_gmt":"2026-05-12T08:56:17","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70664"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"mots-c","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/mots-c\/","title":{"rendered":"MOTS-c"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es MOTS-c?<\/h3>\n<p style=\"margin: 0;\"><strong>MOTS-c<\/strong> (Mitochondrial Open Reading frame of the Twelve S rRNA-c) is a 16-amino-acid mitochondrially-encoded signaling peptide first identified in 2015. In published preclinical studies it acts as an exercise-mimetic and metabolic regulator by activating the AMPK pathway, restoring insulin sensitivity, and modulating nuclear gene expression in response to mitochondrial stress. Supplied in 10\u00a0mg to 40\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1627580-64-6<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>100<\/sub>H<sub>152<\/sub>N<sub>28<\/sub>O<sub>22<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2174.62 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR, 16 amino\u00e1cidos; codificado dentro del gen mitocondrial 12S rRNA)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado (blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para periodos de uso m\u00e1s cortos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es MOTS-c?<\/h2>\n<p><strong>MOTS-c<\/strong> (Marco de Lectura Abierto Mitocondrial del gen 12S rRNA-c) es un p\u00e9ptido de 16 amino\u00e1cidos identificado por primera vez por Lee et al. en <em>Cell Metabolism<\/em> (2015) as a member of the newly recognised class of mitochondrially-derived peptides (MDPs). Unlike every other peptide in the studies catalog \u2014 which are encoded by nuclear DNA and synthesised in the cytoplasm \u2014 MOTS-c is encoded within the mitochondrial 12S rRNA gene and translated by mitochondrial ribosomes. This unusual biological origin makes it a direct intracellular signal of mitochondrial state, and the most-cited member of a peptide class that includes humanin and the SHLP family. The peptide sequence is MRWQEMGYIFYPRKLR, molecular weight approximately 2,175\u00a0Da, empirical formula C<sub>100<\/sub>H<sub>152<\/sub>N<sub>28<\/sub>O<sub>22<\/sub>S<sub>2<\/sub>. El MOTS-c end\u00f3geno se desplaza desde las mitocondrias al n\u00facleo bajo estr\u00e9s metab\u00f3lico y oxidativo, donde regula un programa g\u00e9nico del ciclo del folato \/ metabolismo de la metionina \u2014 un mecanismo sin paralelo entre los p\u00e9ptidos codificados nuclearmente. MOTS-c se suministra como un polvo liofilizado de alta pureza para reconstituci\u00f3n con agua bacteriost\u00e1tica y es <strong>for clinical studies use only<\/strong>. For related metabolic and longevity peptides, see our full <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a>. <\/p>\n<h2>Mecanismo de Acci\u00f3n \u2014 AMPK, Metabolismo de la Glucosa y Translocaci\u00f3n Nuclear<\/h2>\n<p>Lo que diferencia a MOTS-c de los p\u00e9ptidos metab\u00f3licos m\u00e1s antiguos es su <strong>mecanismo de acci\u00f3n trimodal<\/strong> that spans the mitochondrion, the cytoplasm, and the nucleus \u2014 each contributing to the observed metabolic phenotype in published studies:<\/p>\n<ul>\n<li><strong>Activaci\u00f3n de la v\u00eda AMPK<\/strong> \u2014 MOTS-c activa la prote\u00edna quinasa activada por AMP (AMPK), el principal sensor de energ\u00eda celular, aumentando la relaci\u00f3n intracelular AMP:ATP y mediante un mecanismo dependiente del ciclo del folato. La activaci\u00f3n de AMPK desplaza el metabolismo celular hacia el catabolismo: mayor captaci\u00f3n de glucosa mediante translocaci\u00f3n de GLUT4, oxidaci\u00f3n de \u00e1cidos grasos, biog\u00e9nesis mitocondrial a trav\u00e9s de PGC-1\u03b1 y autofagia. Esta es la misma v\u00eda diana de la metformina y el ejercicio, lo que ha valido a MOTS-c la descripci\u00f3n de \u201cp\u00e9ptido mim\u00e9tico del ejercicio\u201d en la literatura publicada.<\/li>\n<li><strong>Sensibilidad a la insulina y disposici\u00f3n de glucosa<\/strong> \u2014 In high-fat-diet rodent models, MOTS-c administration restores insulin-stimulated glucose uptake in skeletal muscle and adipose tissue. The effect is independent of body-weight change in some studies designs, suggesting a direct insulin-sensitising mechanism rather than secondary to weight loss. MOTS-c-treated obese mice show normalised oral glucose tolerance and improved euglycaemic-clamp parameters in published studies.<\/li>\n<li><strong>Translocaci\u00f3n nuclear y expresi\u00f3n g\u00e9nica adaptativa<\/strong> \u2014 Bajo estr\u00e9s metab\u00f3lico u oxidativo, MOTS-c se transloca desde las mitocondrias al n\u00facleo, donde coregula un programa transcripcional centrado en la respuesta antioxidante (NRF2), el ciclo folato-metionina y genes metab\u00f3licos adaptativos. Esta se\u00f1alizaci\u00f3n retr\u00f3grada mitocondria-n\u00facleo es uno de los primeros ejemplos a nivel pept\u00eddico de comunicaci\u00f3n intercompartimental intracelular y es la base de los efectos m\u00e1s amplios de MOTS-c m\u00e1s all\u00e1 de la activaci\u00f3n directa de AMPK.<\/li>\n<\/ul>\n<p>The biological appeal of MOTS-c in metabolic support is the convergence of these three mechanisms onto pathways already known to mediate the benefits of exercise and caloric restriction. Because endogenous MOTS-c declines markedly with age in human serum (~50% reduction across adult lifespan in published cohorts), the peptide has become a frequent target in aging and longevity studies as well as in metabolic syndrome. <\/p>\n<h2>Published Evidence<\/h2>\n<p>MOTS-c is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Metabolic syndrome and obesity studies<\/strong> \u2014 insulin sensitivity, glucose tolerance, body composition in high-fat-diet rodent models; benchmark peptide for AMPK-axis intervention studies (Lee et al., Cell Metabolism 2015; Reynolds et al., Front Physiol 2021)<\/li>\n<li><strong>Modelos precl\u00ednicos de diabetes tipo 2<\/strong> \u2014 modelos de diabetes db\/db, ZDF e inducidos por estreptozotocina; efectos sobre la sensibilidad hep\u00e1tica a la insulina, funci\u00f3n de las c\u00e9lulas beta y sustitutos de HbA1c<\/li>\n<li><strong>Capacidad de ejercicio y biog\u00e9nesis mitocondrial<\/strong> \u2014 resistencia en cinta de correr, VO<sub>2<\/sub>max surrogates, PGC-1\u03b1 expression, mitochondrial DNA copy number in skeletal muscle studies<\/li>\n<li><strong>Aging and longevity studies<\/strong> \u2014 lifespan extension models, age-related insulin resistance, sarcopenia; MOTS-c serum levels decline with age, making it a candidate replacement peptide in geroscience studies<\/li>\n<li><strong>Protecci\u00f3n cardiovascular y renal<\/strong> \u2014 ischaemia-reperfusion injury, oxidative stress markers, mitochondrial dysfunction in cardiac and renal tissue study models<\/li>\n<li><strong>Bone health studies<\/strong> \u2014 diferenciaci\u00f3n de osteoblastos, densidad mineral \u00f3sea, modelos de osteoporosis relacionada con la edad<\/li>\n<li><strong>Comparative mitochondrial peptide studies<\/strong> \u2014 evaluaci\u00f3n comparativa con otros p\u00e9ptidos dirigidos a mitocondrias como <a href=\"https:\/\/medsbase.com\/es\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a>. Consulte la secci\u00f3n de comparaci\u00f3n a continuaci\u00f3n para un an\u00e1lisis metodol\u00f3gico detallado.<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio sobre d\u00f3nde encaja MOTS-c en el panorama de los p\u00e9ptidos metab\u00f3licos y de longevidad, consulte <a href=\"https:\/\/medsbase.com\/es\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> como el p\u00e9ptido mitocondrial can\u00f3nico dirigido a la cardiolipina, <a href=\"https:\/\/medsbase.com\/es\/epitalon\/\">Epital\u00f3n<\/a> for telomere\/longevity studies, and <a href=\"https:\/\/medsbase.com\/es\/nad\/\">NAD+<\/a> for NAD-axis metabolic support. Browse the full <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks MOTS-c in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, short-cycle protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Viales de rango medio para volumenes grandes, con menor volumen de reconstituci\u00f3n por dosis<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle protocols, longevity studies, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials yield greater per-vial dose flexibility and lower per-mg cost; the trade-off is that reconstituted solution must be used within 30 days, so multi-month protocols benefit from larger vials only when the per-week dose is correspondingly high. <\/p>\n<h2>Comparativa \u2014 MOTS-c vs SS-31 (Elamipretida)<\/h2>\n<p>MOTS-c y <a href=\"https:\/\/medsbase.com\/es\/ss-31-elamipretide\/\">SS-31<\/a> are the two most-cited mitochondrially-targeted peptides in current studies. They are mechanistically distinct and complementary, not redundant: MOTS-c is a signalling peptide that activates AMPK and nuclear-encoded adaptive programmes, while SS-31 is a structural peptide that binds cardiolipin in the inner mitochondrial membrane to stabilise the electron transport chain. Users often pair them in mitochondrial-dysfunction models for this reason. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">MOTS-c<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">SS-31 (Elamipretide)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">16 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4 amino\u00e1cidos (tetrap\u00e9ptido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origen<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Codificado en el ADN mitocondrial (gen 12S rRNA)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u00e9ptido sint\u00e9tico Szeto-Schiller<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mecanismo primario<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Activaci\u00f3n de AMPK, expresi\u00f3n g\u00e9nica nuclear<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Uni\u00f3n a cardiolipina, estabilizaci\u00f3n de la cadena de transporte de electrones<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Objetivo celular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mitocondria \u2192 citoplasma \u2192 n\u00facleo<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Solo membrana mitocondrial interna<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosis t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5\u201315 mg, 1\u20133 veces por semana<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u20135 mg, diariamente<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sensibilidad a la insulina, capacidad de ejercicio, envejecimiento<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Isquemia card\u00edaca, disfunci\u00f3n mitocondrial renal<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Combinaci\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Frequently co-administered with SS-31 in mitochondrial studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Frecuentemente coadministrado con MOTS-c<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The two peptides act on different layers of mitochondrial biology \u2014 MOTS-c regulates metabolic transcription, SS-31 stabilises membrane architecture \u2014 so they address non-overlapping studies questions. For metabolic\/insulin sensitivity, MOTS-c is the default first choice. For cardiac, renal, or ischaemia-reperfusion mitochondrial protection, SS-31 is the canonical comparator. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> Almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su envase original para existencias de trabajo a corto plazo. Para almacenamiento a largo plazo sin abrir, congele a \u221220 \u00b0C. El MOTS-c liofilizado es estable bajo refrigeraci\u00f3n hasta 24 meses y a \u221220 \u00b0C hasta 36 meses. Evite ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo liofilizado. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inyecte agua bacteriost\u00e1tica por la pared lateral del vial de p\u00e9ptido (no directamente sobre el polvo liofilizado). Para un vial de 10 mg, 2,0 mL de agua bacteriost\u00e1tica producen una concentraci\u00f3n de trabajo de 5 mg\/mL: 10 marcas en una jeringa de insulina U-100 equivalen a 500 mcg. Agite suavemente, no <strong>ajuste<\/strong> shake \u2014 and allow 2\u20135 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because MOTS-c is typically dosed 1\u20133 times weekly in protocols, a single reconstituted 10\u00a0mg vial typically supports 2\u20133 weeks of dosing depending on the target dose and frequency. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is MOTS-c used for in studies?<\/h3>\n<p>MOTS-c is used in studies investigating insulin sensitivity, type 2 diabetes models, exercise capacity, mitochondrial biogenesis, aging and longevity, cardiovascular ischaemia-reperfusion injury, renal mitochondrial dysfunction, and bone health. It is the most-cited mitochondrially-encoded signalling peptide in the published literature and serves as a benchmark for AMPK-axis interventions. MOTS-c is <strong>ajuste<\/strong> FDA-approved and is supplied here strictly for clinical studies use only. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia el MOTS-c del SS-31 (Elamipretida)?<\/h3>\n<p>MOTS-c is a 16-amino-acid signalling peptide encoded by mitochondrial DNA that activates AMPK and regulates nuclear gene expression. SS-31 is a 4-amino-acid synthetic Szeto-Schiller peptide that binds cardiolipin in the inner mitochondrial membrane to stabilise the electron transport chain. The two address different layers of mitochondrial biology \u2014 MOTS-c at the metabolic-transcription level, SS-31 at the membrane-architecture level \u2014 and are frequently co-administered in mitochondrial-dysfunction studies. <\/p>\n<h3>What is the typical MOTS-c dose?<\/h3>\n<p>Los protocolos precl\u00ednicos publicados suelen utilizar 5\u201315 mg por administraci\u00f3n en modelos de roedores, administrados 1\u20133 veces por semana durante ciclos de 4\u201312 semanas. Un vial de 10 mg reconstituido con 2,0 mL de agua bacteriost\u00e1tica produce 5 mg\/mL \u2014 10 divisiones en una jeringa U-100 equivalen a 500 mcg. <\/p>\n<h3>\u00bfEst\u00e1 aprobado el MOTS-c por la FDA?<\/h3>\n<p>No. MOTS-c is not approved by the FDA, EMA, MHRA, or any other regulator for human therapeutic use. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar el MOTS-c?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C para existencias de trabajo a corto plazo, o \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar dentro de los 30 d\u00edas. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan el p\u00e9ptido. Proteja de la luz directa en todo momento. <\/p>\n<h3>\u00bfC\u00f3mo reconstituyo el MOTS-c?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no sobre el polvo liofilizado), agite suavemente y permita de 2 a 5 minutos para la disoluci\u00f3n completa. No <strong>ajuste<\/strong> agite el vial. Una soluci\u00f3n correctamente reconstituida es transparente e incolora. Para un vial de 10 mg + 2.0 mL de diluyente, la concentraci\u00f3n de trabajo es de 5 mg\/mL. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries MOTS-c in 10\u00a0mg, 20\u00a0mg, and 40\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>\u00bfPor qu\u00e9 se llama al MOTS-c un p\u00e9ptido \u201cmim\u00e9tico del ejercicio\u201d?<\/h3>\n<p>The term derives from MOTS-c&#8217;s activation of AMPK and downstream effects on glucose uptake, fatty acid oxidation, and mitochondrial biogenesis \u2014 the same intracellular pathway responsible for many of the metabolic adaptations to exercise. In published studies, MOTS-c administration replicates several phenotypes of exercise training in sedentary animals: improved insulin sensitivity, increased treadmill endurance, and elevated PGC-1\u03b1 expression in skeletal muscle. The metaphor is widely used in geroscience and metabolic-syndrome literature. <\/p>\n<h3>Can MOTS-c and SS-31 be stacked in studies?<\/h3>\n<p>Yes. MOTS-c and SS-31 act on different layers of mitochondrial biology and are frequently co-administered in preclinical mitochondrial-dysfunction studies. MOTS-c regulates metabolic transcription via AMPK; SS-31 stabilises the inner-membrane lipid environment. Their mechanisms are complementary rather than overlapping, which makes the combination useful in study models of multi-axis mitochondrial decline. <\/p>\n<h3>Does MOTS-c cause side reported effects?<\/h3>\n<p>Published preclinical studies has reported a notably clean safety profile at typical doses in rodent models, with no consistent off-target signals and good tolerability across 4\u201312 week dosing cycles. MOTS-c is structurally an endogenous human peptide, which reduces the risk of antibody-mediated reactions seen with engineered analogs. Long-term human safety data are not available because human trials are still in early stages. <\/p>\n<h3>\u00bfCu\u00e1l es la vida media de MOTS-c?<\/h3>\n<p>In preclinical studies, MOTS-c has an estimated plasma half-life of approximately 3\u20134 hours following subcutaneous administration. The relatively short systemic half-life is offset by intracellular accumulation and the peptide&#8217;s role as an intracellular signalling molecule rather than a circulating hormone \u2014 effects persist beyond the plasma clearance window in study models. <\/p>\n<h3>\u00bfPor qu\u00e9 disminuye el MOTS-c end\u00f3geno con la edad?<\/h3>\n<p>Published cohort data show roughly a 50% decline in human serum MOTS-c levels between young and aged adults. The mechanism is not fully understood but is thought to relate to age-associated mitochondrial DNA mutations, declining mitochondrial transcription, and reduced biosynthesis of mitochondrially-encoded peptides in general. The age-related decline is one reason MOTS-c has attracted strong interest in longevity and geroscience studies. <\/p>\n<h3>How long does MOTS-c take to show effects in preclinical studies?<\/h3>\n<p>Los efectos agudos sobre la fosforilaci\u00f3n de AMPK y la captaci\u00f3n de glucosa son detectables horas despu\u00e9s de la administraci\u00f3n. Los efectos sobre la sensibilidad a la insulina y la composici\u00f3n corporal en modelos de roedores con dieta alta en grasas suelen ser estad\u00edsticamente significativos despu\u00e9s de 2 a 4 semanas de dosificaci\u00f3n regular. Las mejoras en la capacidad de ejercicio (resistencia en cinta, sustitutos de VO<sub>2<\/sub>max surrogates) accrue over 4\u20138 weeks of continuous dosing. <\/p>\n<h3>\u00bfPuedo pedir MOTS-c para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda MOTS-c a todo el mundo desde nuestra red dedicada de env\u00edo de p\u00e9ptidos. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo independiente de p\u00e9ptidos. Todos los pedidos se env\u00edan en embalaje con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Mitochondrial, and Longevity Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/ss-31-elamipretide\/\"><strong>SS-31 (Elamipretide)<\/strong><\/a> \u2014 Tetrap\u00e9ptido mitocondrial que se une a la cardiolipina \u2014 estabilizador can\u00f3nico de la membrana interna<\/li>\n<li><a href=\"\/es\/nad\/\"><strong>NAD+<\/strong><\/a> \u2014 Nicotinamide adenine dinucleotide \u2014 sirtuin\/longevity-axis metabolic support<\/li>\n<li><a href=\"\/es\/epitalon\/\"><strong>Epital\u00f3n<\/strong><\/a> \u2014 AEDG pineal tetrapeptide \u2014 telomerase activation and longevity studies<\/li>\n<li><a href=\"\/es\/semaglutide\/\"><strong>Semaglutida<\/strong><\/a> \u2014 Long-acting GLP-1 agonist \u2014 glycaemic and body-weight studies<\/li>\n<li><a href=\"\/es\/retatrutide\/\"><strong>Retatrutida<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 multi-axis metabolic support<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Comparar p\u00e9ptidos dirigidos a las mitocondrias<\/strong><\/p>\n<p style=\"margin: 0;\">Explora el \u00e1mbito m\u00e1s amplio <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a> para p\u00e9ptidos mitocondriales y metab\u00f3licos, incluyendo <a href=\"https:\/\/medsbase.com\/es\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin-targeted membrane studies, <a href=\"https:\/\/medsbase.com\/es\/nad\/\">NAD+<\/a> for sirtuin-axis longevity studies, and <a href=\"https:\/\/medsbase.com\/es\/epitalon\/\">Epital\u00f3n<\/a> for telomere-axis longevity studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 P\u00e9ptido de se\u00f1alizaci\u00f3n codificado mitocondrialmente<br \/>\n\u2705 Activa la v\u00eda metab\u00f3lica AMPK<br \/>\n\u2705 Mejora la sensibilidad a la insulina<br \/>\n\u2705 Ejercicio-mim\u00e9tico en modelos precl\u00ednicos<br \/>\n\u2705 Longevity &amp; geroscience compound<\/p>\n<p><strong>MOTS-c<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70967,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6272,5441],"class_list":["post-70664","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-mots-c","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70664"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70967"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70664"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70664"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70664"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}